The EMPA-HEART CardioLink-6 trial showed that inhibiting SGLT2 with empagliflozin was accompanied with a significant reduction in LVM in patients with type 2 diabetes mellitus and coronary artery disease.39 This evidence concerns the gene SLC5A2 and coronary artery disorder.